Nanocan Therapeutics
Nanocan Therapeutics Corporation is an early-stage biotechnology company developing novel drug-delivery nanotechnology for more precise and targeted treatment of cancer and respiratory diseases. They aim to unlock local immune-driven potential and reduce side effects through innovative therapies, partnering with leading academic institutions to develop shorter and efficient combination treatments to improve patient lives and global access to care.
Industries
Nr. of Employees
small (1-50)
Nanocan Therapeutics
Products
Therapeutic candidate targeting prostate cancer
Nanoparticle-delivered therapeutic candidate intended for localized treatment of prostate cancer to improve local efficacy and reduce systemic side effects.
Therapeutic candidate targeting pancreatic cancer
Nanoparticle-delivered therapeutic candidate intended for localized treatment of pancreatic cancer to concentrate therapy at the disease site and limit systemic exposure.
Therapeutic candidate targeting cervical cancer
Nanoparticle-delivered therapeutic candidate intended for localized treatment of cervical cancer to improve local control and reduce systemic side effects.
Therapeutic candidate targeting breast cancer (next-tier)
Planned nanoparticle-delivered therapeutic candidate intended for localized treatment of breast cancer as part of a subsequent product rollout.
Therapeutic candidate targeting liver cancer (next-tier)
Planned nanoparticle-delivered therapeutic candidate intended for localized treatment of liver cancer as part of a subsequent product rollout.
Therapeutic candidate targeting lung cancer (next-tier)
Planned nanoparticle-delivered therapeutic candidate intended for localized treatment of lung cancer as part of a subsequent product rollout.
Therapeutic candidate targeting prostate cancer
Nanoparticle-delivered therapeutic candidate intended for localized treatment of prostate cancer to improve local efficacy and reduce systemic side effects.
Therapeutic candidate targeting pancreatic cancer
Nanoparticle-delivered therapeutic candidate intended for localized treatment of pancreatic cancer to concentrate therapy at the disease site and limit systemic exposure.
Therapeutic candidate targeting cervical cancer
Nanoparticle-delivered therapeutic candidate intended for localized treatment of cervical cancer to improve local control and reduce systemic side effects.
Therapeutic candidate targeting breast cancer (next-tier)
Planned nanoparticle-delivered therapeutic candidate intended for localized treatment of breast cancer as part of a subsequent product rollout.
Therapeutic candidate targeting liver cancer (next-tier)
Planned nanoparticle-delivered therapeutic candidate intended for localized treatment of liver cancer as part of a subsequent product rollout.
Therapeutic candidate targeting lung cancer (next-tier)
Planned nanoparticle-delivered therapeutic candidate intended for localized treatment of lung cancer as part of a subsequent product rollout.
Services
Collaborative research agreements and partnerships with academic institutions to co-develop preclinical therapeutic candidates and translate laboratory findings.
Collaborative research agreements and partnerships with academic institutions to co-develop preclinical therapeutic candidates and translate laboratory findings.
Expertise Areas
- Nanoparticle drug delivery
- Oncology therapeutics development
- Respiratory disease therapeutics
- Combination therapy design
Key Technologies
- Nanoparticle-based drug carriers
- Targeted/localized delivery techniques
- Nanomaterials formulation
- Combination therapy platforms